Mandeep S. Sagoo

Prof. Mandeep S. Sagoo

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2018 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
LCLyndon da Cruz
Lyndon da Cruz
KFKate Fynes
Kate Fynes
OGOdysseas Georgiadis
Odysseas Georgiadis
JKJulie Kerby
Julie Kerby
YLYvonne H Luo
Yvonne H Luo
PCPeter J Coffey
Peter J Coffey

1 May 2020 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
GGGlobal Retinoblastoma Study Group
Global Retinoblastoma Study Group
IFIdo Didi Fabian
Ido Didi Fabian
EAElhassan Abdallah
Elhassan Abdallah
SAShehu U. Abdullahi
Shehu U. Abdullahi
RARula A. Abdulqader
Rula A. Abdulqader
RBRichard Bowman
Richard Bowman
Retinoblastoma, the most common eye cancer of childhood, is fatal if left untreated. Prognosis of patients with retinoblastoma in high-income countries (HICs) has improved over the past 50 years, now reaching a near 100% disease-free survival rate.1-3 This is attributed to several factors, including (1) creation of specialized referral centers, (2) decoding of the genetic basis of the disease, (3) formation of screening programs, and (4) the introduction of chemotherapy.4 In HICs, retinoblastoma is a curable disease, and attention has now shifted to eye salvage5,6 and improvement of quality of life.7 In low- and middle-income countries (LMICs), where more than 80% of global retinoblastoma cases arise, the prognosis is poor, and it is assumed that this is because of delayed diagnosis and treatment.8-10 Publications from LMICs are scarce, and many countries do not report their retinoblastoma data.11 The stage of retinoblastoma at the time of diagnosis in low-income, middle-income, and high-income countries has not been surveyed globally. This information is important for policy and health care planning at national and international levels.

1 September 2014 in Survey of Ophthalmology
Verified
Journal Article
Open access
MSMandeep S. Sagoo
Mandeep S. Sagoo
HMHemal Mehta
Hemal Mehta
ASAndrew J. Swampillai
Andrew J. Swampillai
VCVictoria Cohen
Victoria Cohen
SASepideh Z. Amin
Sepideh Z. Amin
SLSue Lightman
Sue Lightman
Primary intraocular lymphoma (PIOL) is an ocular malignancy that is a subset of primary central system lymphoma (PCNSL). Approximately one-third of PIOL patients will have concurrent PCNSL at presentation, and 42-92% will develop PCNSL within a mean of 8-29 months. Although rare, the incidence has been rising in both immunocompromised and immunocompetent populations. The majority of PIOL is diffuse large B-cell lymphoma, though rare T-cell variants are described. Recently, PIOL has been classified by main site of involvement in the eye, with vitreoretinal lymphoma as the most common type of ocular lymphoma related to PCNSL. Diagnosis remains challenging for ophthalmologists and pathologists. PIOL can masquerade as noninfectious or infectious uveitis, white dot syndromes, or occasionally as other neoplasms such as metastatic cancers. Laboratory diagnosis by cytology has been much aided by the use of immunocytochemistry, flow cytometry, biochemical finding of interleukin changes (IL10:IL6 ratio > 1), and cellular microdissection with polymerase chain reaction amplification for clonality. Use of several tests improves the diagnostic yield. Approaches to treatment have centered on systemic methotrexate-based chemotherapy, often with cytarabine (Ara-C) and radiotherapy. Use of intravitreal chemotherapy with methotrexate (0.4 mg/0.1 mL) is promising in controlling ocular disease, and intravitreal rituximab (anti-CD20 monoclonal antibody) has also been tried. Despite these advances, prognosis remains poor.

11 January 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
IFIdo D. Fabian
Ido D. Fabian
ZOZerrin Onadim
Zerrin Onadim
EKEsin Karaa
Esin Karaa
CDCatriona Duncan
Catriona Duncan
TCTanzina Chowdhury
Tanzina Chowdhury
MSMandeep S. Sagoo
Mandeep S. Sagoo

30 October 2013 in Tropical Medicine & International Health
Verified
Journal Article
Open access
PDF file
SGStephen Gichuhi
Stephen Gichuhi
MSMandeep S. Sagoo
Mandeep S. Sagoo
HWHelen A. Weiss
Helen A. Weiss
MBMatthew J. Burton
Matthew J. Burton
Objectives: To describe the epidemiology and an aetiological model of ocular surface squamous neoplasia (OSSN) in Africa.Methods: Systematic and non‐systematic review methods were used. Incidence was obtained from the International Agency for Research on Cancer. We searched PubMed, EMBASE, Web of Science and the reference lists of articles retrieved. Meta‐analyses were conducted using a fixed‐effects model for HIV and cigarette smoking and random effects for human papilloma virus (HPV).Results: The incidence of OSSN is highest in the Southern Hemisphere (16° South), with the highest age‐standardised rate (ASR) reported from Zimbabwe (3.4 and 3.0 cases/year/100 000 population for males and females, respectively). The mean ASR worldwide is 0.18 and 0.08 cases/year/100 000 among males and females, respectively. The risk increases with exposure to direct daylight (2–4 h, OR = 1.7, 95% CI: 1.2–2.4 and ≥5 h OR = 1.8, 95% CI: 1.1–3.1) and outdoor occupations (OR = 1.7, 95% CI: 1.1–2.6). Meta‐analysis also shows a strong association with HIV (6 studies: OR = 6.17, 95% CI: 4.83–7.89) and HPV (7 studies: OR = 2.64, 95% CI: 1.27–5.49) but not cigarette smoking (2 studies: OR = 1.40, 95% CI: 0.94–2.09). The effect of atopy, xeroderma pigmentosa and vitamin A deficiency is unclear.Conclusions: Africa has the highest incidence of OSSN in the world, where males and females are equally affected, unlike other continents where male disease predominates. African women probably have increased risk due to their higher prevalence of HIV and HPV infections. As the survival of HIV‐infected people increases, and given no evidence that anti‐retroviral therapy (ART) reduces the risk of OSSN, the incidence of OSSN may increase in coming years.

1 December 2014 in Experimental Eye Research
Verified
Journal Article
Open access
SGStephen Gichuhi
Stephen Gichuhi
SOShin-ichi Ohnuma
Shin-ichi Ohnuma
MSMandeep S. Sagoo
Mandeep S. Sagoo
MBMatthew J. Burton
Matthew J. Burton
The incidence of ocular surface squamous neoplasia (OSSN) is strongly associated with solar ultraviolet (UV) radiation, HIV and human papilloma virus (HPV). Africa has the highest incidence rates in the world. Most lesions occur at the limbus within the interpalpebral fissure particularly the nasal sector. The nasal limbus receives the highest intensity of sunlight. Limbal epithelial crypts are concentrated nasally and contain niches of limbal epithelial stem cells in the basal layer. It is possible that these are the progenitor cells in OSSN. OSSN arises in the basal epithelial cells spreading towards the surface which resembles the movement of corneo-limbal stem cell progeny before it later invades through the basement membrane below. UV radiation damages DNA producing pyrimidine dimers in the DNA chain. Specific CC → TT base pair dimer transformations of the p53 tumour-suppressor gene occur in OSSN allowing cells with damaged DNA past the G1-S cell cycle checkpoint. UV radiation also causes local and systemic photoimmunosuppression and reactivates latent viruses such as HPV. The E7 proteins of HPV promote proliferation of infected epithelial cells via the retinoblastoma gene while E6 proteins prevent the p53 tumour suppressor gene from effecting cell-cycle arrest of DNA-damaged and infected cells. Immunosuppression from UV radiation, HIV and vitamin A deficiency impairs tumour immune surveillance allowing survival of aberrant cells. Tumour growth and metastases are enhanced by; telomerase reactivation which increases the number of cell divisions a cell can undergo; vascular endothelial growth factor for angiogenesis and matrix metalloproteinases (MMPs) that destroy the intercellular matrix between cells. Despite these potential triggers, the disease is usually unilateral. It is unclear how HPV reaches the conjunctiva.